|Bid||9.69 x 1200|
|Ask||11.52 x 1000|
|Day's Range||9.86 - 10.77|
|52 Week Range||9.25 - 15.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
Mirum Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today reported financial results for the quarter ended June 30, 2019 and provided an update on its clinical programs.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) recently went public, offering 5 million shares at $15 each. With the IPO quiet period expiring, analysts are kicking off coverage of the stock. The Analyst ...
FOSTER CITY, Calif., July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $75,000,000. The shares are expected to begin trading on the Nasdaq Global Market on July 18, 2019 under the symbol "MIRM".
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Douyu International Holdings Ltd (DOYU) will issue nearly 67.4 million ...
Foster City, California-based Mirum Pharmaceuticals is planning a 5-million share IPO at an estimated price range of $14-$16, according to an amended prospectus filed with the SEC July 8. The company said in the filing that certain of its shareholders, directors and their affiliated entities, have expressed interest in purchasing an aggregate of up to about $35 million worth of shares. Mirum is a biopharma company, which focuses on developing novel therapies for debilitating liver diseases.